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Abstract
Background: Despite the increasing annual incidence of hepatocellular carcinoma (HCC) in the USA,
now estimated at 2.7 cases per 100 000 population, only a small proportion of patients receive treatment
and 5-year survival rates range from 9% to 17%.
Objectives: The present study examines the effects of multimodal treatment on survival in a mixed-
stage HCC cohort, focusing on the impact of radical therapy in patients with Barcelona Clinic Liver
Cancer (BCLC) stage B disease.
Methods: A retrospective review of the medical records of 254 patients considered for HCC treatment
between 2003 and 2011 at a large tertiary referral centre was conducted.
Results: A total of 195 (76.8%) patients were treated with a median of two liver-directed interventions.
Median survival time was 16 months. In proportional hazards analysis, radiofrequency ablation (RFA) and
resection were associated with significantly improved 1- and 5-year survival among patients with BCLC
stage 0–A disease. In patients with BCLC stage B disease, RFA conferred a survival benefit at 1 year and
resection was associated with significantly improved survival at 5 years.
Conclusions: As one of few studies to track the complete course of sequential HCC therapies, the
findings of the present study suggest that HCC patients with intermediate-stage (BCLC stage B) disease
may benefit from aggressive interventions not currently included in societal guidelines.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of
cancer-related mortality worldwide; approximately 750 000 new
cases are diagnosed and nearly as many attributable deaths occur
per year.1 In the USA, annual incidence increased by approxi-
mately 3.5% per year from 2001 to 2006, and is now 2.7 per
100 000 persons. This rate is expected to rise through the next
decade.2,3 In the USA, the major aetiologic agents are chronic
hepatitis C virus (HCV) or hepatitis B virus (HBV) infection.2
Excessive alcohol consumption and non-alcoholic steatohepatitis
are also implicated, either as amplifiers of the effects of viral
hepatitis or as independent risk factors.4,5 The United States
Department of Veterans Affairs (VA) has been disproportionately
affected by HCC, largely because of the high incidence of chronic
HCV infection among VA patients (5.4%) compared with that in
the general US population (1.8%). Currently, 173 000 VA patients
are known to be chronically infected with HCV.6 Over the past
decade, the VA has seen a five-fold increase in HCC cases.6–8
In its earlier stages, HCC can be cured with aggressive therapies,
but the optimal treatment strategy for patients in the intermediate
Funding: Veterans Affairs Merit Award Program (1I01-CX000295-01A1)
andVeterans Affairs Hepatitis C Resource Center. The funders had no role in
study design, data collection and analysis, decision to publish or preparation
of the manuscript.
DOI:10.1111/hpb.12214 HPB
HPB 2014, 16, 758–767 © 2014 International Hepato-Pancreato-Biliary Association
stages of HCC has not been well established.3,9,10 Although treat-
ment at any stage of HCC has been associated with survival
benefits, only a small proportion of HCC patients receive any
treatment over the course of their disease.3,11,12 Among US patients
diagnosed with HCC between 1998 and 2008, 76% received no
reported intervention. Although different treatment modalities
are often employed sequentially, many studies report only on the
first HCC therapy used and thus fail to capture the entire treat-
ment experience.12–16 Other studies focus only on liver transplan-
tation, the most curative intervention.17,18 Transplantation
opportunities in HCC patients are limited by advanced stage at
diagnosis, comorbid conditions, inadequate social support and
constrained resources. There is a paucity of literature examining
treatment patterns and outcomes in HCC patients in typical prac-
tice settings in which transplantation is not frequently employed.
Current societal guidelines recommend that only patients in the
earliest stages of HCC should receive potentially curative HCC
therapies, which typically include liver transplantation, hepatic
resection and radiofrequency ablation (RFA).19,20 There is increas-
ing evidence, however, in support of the extended use of some or
all of these treatments in selected patients with intermediate-stage
HCC.21–23 This retrospective medical records review was con-
ducted to examine multimodal HCC treatment in a large tertiary
referral veterans hospital. The study demonstrates that patients
with both early- and intermediate-stage HCC can achieve a sig-
nificant survival benefit from potentially curative interventions
that are often reserved for early-stage patients.
Materials and methods
Ethics statement
This study was conducted in accordance with the ethical
principles stated in the Declaration of Helsinki and in a
manner consistent with good clinical practice and applicable
regulatory requirements.24 A waiver of consent for the retrospec-
tive review of records for this specific study of HCC patient
outcomes was obtained from the University of California San
Francisco Institutional Review Board and approved by the San
Francisco VA Medical Center (SFVAMC) Research and Develop-
ment Committee.
Patient population and data collection
The study cohort included all previously untreated patients
referred to SFVAMC for consideration for HCC treatment
between April 2003 and April 2011. Patients in whom HCC was
confirmed by histology, cytology or cross-sectional imaging, such
as computed tomography (CT) or magnetic resonance imaging
(MRI), were included. Those with equivocal cases of HCC or with
heterogeneous tumour cells (i.e. HCC and cholangiocarcinoma)
were excluded. The study end date was 28 February 2012.
Patient demographic characteristics and baseline clinical risk
factors, including results of laboratory studies and tumour
staging, were those recorded in the medical record on the date
closest to the index visit. Infection with HBV, HCV or human
immunodeficiency virus (HIV) was confirmed using standard cri-
teria. Alcohol abuse was defined as a longstanding history of
excessive alcohol consumption (more than three standard drinks
per day) or a history of alcohol-related medical complications.25
Raw Model of End-stage Liver Disease (MELD) scores (i.e.
without consideration for HCC exception points) and Child–
Pugh classes were calculated from the medical record data accord-
ing to standard methods.26–28 Using this information, tumours
were staged by the investigators according to the Barcelona Clinic
Liver Cancer (BCLC) classification system, which is widely
accepted.20,29
Treatment dates and modalities included those from the index
visit to the study end date. Treatment decisions were made at
multidisciplinary disease management conferences attended by
hepatologists, surgeons, radiologists and medical oncologists, as
guided by the National Comprehensive Cancer Network and the
American Association for the Study of Liver Disease.19,20,29 In brief,
surgical resection was considered for single tumours without vas-
cular invasion or distant disease in the presence of adequate liver
function. Radiofrequency ablation was most often used for single
tumours of 3–5 cm in size in a favourable location in patients who
did not fulfil the resection criteria. Other liver-directed therapies,
henceforth termed ‘locoregional therapies’ (LRTs), include
transarterial (chemo)embolization [TA(C)E], microwave ablation
(MWA) and percutaneous ethanol injection (PEI). Locoregional
therapies were used to achieve initial control of tumours prior to
radical therapy or solely as palliative treatment. Transarterial
(chemo)embolization was most often used in patients with several
small tumours or impaired liver function. Percutaneous ethanol
injection was generally only used for tumours of <3 cm in size.
Further interventions (other than liver transplant) were per-
formed most commonly for recurrent HCC, although some
lesions required serial therapies. Repeat contrast CT or MRI was
obtained 1–3 months after each treatment, and then serially at
3–6-month intervals. Guided by the consensus in the literature,
patients were grouped into one of five treatment groups in declin-
ing order of efficacy, based on the most efficacious treatment they
had ever received: (i) liver transplantation; (ii) surgical resection;
(iii) RFA; (iv) LRT, and (v) no procedural intervention. (Patients
who received chemotherapy only and those who received no treat-
ment were combined for analytic purposes, but are described
separately in Table 3.)
Major outcomes
The major outcomes explored in this study were: (i) median sur-
vival time; (ii) overall survival by BCLC stage at the index visit,
and (iii) 1-year and 5-year hazard ratios (HRs) for survival, strati-
fied by BCLC stage (0–A and B), for themost efficacious treatment
modality used.
Data sources
Study data were abstracted from the VA’s comprehensive elec-
tronic medical record system by two investigators, using a stand-
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ardized search algorithm. Deaths were obtained from the medical
record and confirmed by cross-referencing with the Social Secu-
rity Death Index to ensure completeness. Data validation was
conducted by a third investigator on a random sample of patient
charts to confirm accuracy.
Statistical analysis
Chi-squared tests were used for categorical data analyses and
analysis of variance (anova) was used to assess differences in
mean values of continuous variables. To obtain P-values, Fisher’s
exact test was used to correct for small sample size, and continu-
ous variables were rank-transformed. Cox proportional hazards
models and Kaplan–Meier curves were generated for survival
analyses. Survival time was measured from the date of the index
visit to the date of death or confirmed follow-up at 1 year and 5
years. Statistical analyses were performed using sas Version 9.2
(SAS Institute, Inc., Cary, NC, USA).
Results
A total of 254 patients with newly diagnosed HCC were evaluated
at SFVAMC for consideration of treatment between April 2003
and April 2011. All patients were classified by BCLC stage at the
index visit. The baseline demographic and clinical characteristics
of the cohort are presented in Table 1. All patients were followed
through to the end of the study period or to the date of death. The
mean ± standard deviation (SD) age at the index visit was 61.8 ±
8.5 years. As expected in a veteran population, all but two patients
were men. Notably, 80.0% of patients had chronic HCV infection
and 62.6% had histories of alcohol abuse. Only 2.4% were iden-
tified as having HBV-related HCC.
Raw MELD score, alpha-fetoprotein (AFP) level and Child–
Pugh class were predictably higher in more advanced BCLC stages
(P < 0.0001 for eachmarker) (Table 1).Only 6.3% of patients were
classified as being of Child–Pugh class C status, but significant
proportions of early- and intermediate-stage patients had Child–
Pugh class B liver disease at presentation (40.8% and 47.6% of
subjects with BCLC stage A and B disease, respectively). Data on
the number and size of HCC lesions at the index visit are sum-
marized in Table 2.
Among the 195 patients who were given liver-directed therapy,
the median number of treatments received was two (range: one
to 11) (Table 3). Eleven (4.3%) patients received transplants, of
whom 10 had BCLC stage 0–A and one had BCLC stage B disease
at baseline. Of the 53 surgical resections performed, 71.7% were
segmental or multi-segmental, 17.0% were hemi-hepatectomies
and 11.3% were extended hemi-hepatectomies. A total of 28.0%
of these procedures were completed laparoscopically (data not
shown). Sixty RFAs were performed, representing 23.6% of all
procedures. Locoregional therapies represented the most fre-
quently used treatment type: 202 such procedures were per-
formed. A total of 51 (20.1%) patients received no treatment and
eight (3.1%) received only chemotherapy.
With regard to the first treatment modality used, 65.4% of
patients with BCLC stage 0–A disease received either surgical
resection (30.9%) or RFA (34.5%), compared with 28.6% of those
with BCLC stage B disease, the majority (55.2%) of whom
received LRT first (P < 0.0001). The first treatment received was
not necessarily the most potentially curative; 24 (12.7%) of the
189 patients who underwent more than one treatment modality
received a more aggressive form of treatment subsequent to their
first. Twelve patients who received LRT first later underwent RFA
or liver resection (data not shown).
Patients who presented with lower baseline MELD scores and
BCLC status were significantly more likely to undergo radical
therapy. Overall, 40.4% of patients with MELD scores of < 15
underwent liver resection or RFA, whereas 20.7% of those with
baseline MELD scores of ≥15 did so. Mean ± SD baseline MELD
scores were 9.51 ± 3.62 in patients undergoing at least one resec-
tion or RFA treatment and 11.32 ± 4.17 in patients who did not
receive these treatments (P < 0.0001). Overall, 58.0% of patients
with BCLC stage 0–A disease and 39.0% of those with BCLC stage
B disease received these treatments, whereas only 10.8% of those
with BCLC stage C or D disease at baseline did so (P < 0.0001).
Patients submitted to the most potentially efficacious therapies
(Table 3), in declining order, included: 11 (4.3%) patients submit-
ted to liver transplant, 52 (20.5%) patients submitted to surgical
resection, 45 (17.7%) patients submitted to RFA, and 87 (34.3%)
patients submitted to LRT. Not surprisingly, a statistically signifi-
cantly higher proportion of patients with stage 0–A disease
received transplant, resection or RFA compared with those with
BCLC stage B or C–D disease (P < 0.0001).
Barcelona Clinic Liver Cancer stage-specific survival data are
presented in Table 4. The median length of survival across the
cohort was 16 months, and ranged from 23.5 months in patients
with BCLC stage 0 disease to 3months in thosewith stageDdisease
(P < 0.0001). Overall, 63.2% of patients survived 1 year and 11.6%
survived 5 years. All patients with BCLC stage 0 disease and 83.3%
of those with stage A disease were alive at 1 year, whereas only
29.2% of patients with stage C and 29.4% of those with stage D
disease remained alive (P < 0.0001).At 5 years, 33.3% and 25.5%of
patients with BCLC stage 0 and A disease, respectively, remained
alive, whereas only 9.4% of patients with BCLC stage B, none with
stage C and only one with stage D disease remained alive (P <
0.0004). Kaplan–Meier curves for survival at 1 year and 5 years,
stratified by index BCLC stage, are presented in Fig. S1 (online).
The 11 transplant recipients ranged in age from 49 years to 66
years at the index visit. Two had BCLC stage 0 disease, eight had
stage A disease and one had stage B disease. Each received at least
one intervention prior to transplantation and eight received two
or more pre-transplant treatments. The mean length of waiting
time from the initial diagnosis of HCC to liver transplantation
was 24 months (range: 11–62 months). The median length of
follow-up between the initial visit and either death or the study
end date was 65 months (data not shown). Two transplant
patients died prior to the study cut-off date. The other nine
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Table 1 Characteristics of the study population by Barcelona Clinic Liver Cancer (BCLC) stage of hepatocellular carcinoma (HCC) at the
index visit
Characteristics BCLC stage Total
(n = 254)
P-valuec
0
(n = 8)
A
(n = 76)
B
(n = 105)
C
(n = 48)
D
(n = 17)
Age, years, mean ± SD 58.7 ± 3.8 60.3 ± 7.7 63.5 ± 9.4 62.3 ± 8.1 59.1 ± 7.1 61.8 ± 8.5 0.06
Male, n (%) 8 (100%) 74 (97.4%) 105 (100%) 48 (100%) 17 (100%) 252 (99.2%) 0.13
BMI, kg/m2, mean ± SD 27.6 ± 4.6 28.9 ± 5.6 28.6 ± 5.8 27.9 ± 5.0 28.4 ± 7.1 28.5 ± 5.6 0.94
Ethnicity, n (%)
White 3 (37.5%) 43 (56.6%) 56 (53.3%) 31 (64.6%) 9 (52.9%) 142 (55.9%) 0.91
African-American 3 (37.5%) 18 (23.7%) 25 (23.8%) 7 (14.6%) 4 (23.5%) 57 (22.4%)
Hispanic 2 (25.0%) 11 (14.5%) 16 (15.2%) 6 (12.6%) 2 (11.8%) 37 (14.6%)
Unknown 0 4 (5.3%) 8 (7.6%) 4 (8.3%) 2 (11.8%) 18 (7.1%)
Risk factors for HCC, n (%)
Chronic hepatitis C 8 (100%) 65 (85.5%) 78 (74.3%) 39 (81.3%) 13 (76.5%) 203 (80.0%) 0.24
Chronic hepatitis B 1 (12.5%) 4 (5.3%) 1 (1.0%) 0 0 6 (2.4%) 0.08
Alcohol abuse 2 (25.0%) 49 (64.5%) 63 (60.0%) 31 (64.6%) 14 (82.4%) 159 (62.6%) 0.09
HIV 0 0 2 (1.9%) 0 0 2 (0.8%) 0.75
Other liver disease 1 (12.5%) 1 (1.3%) 1 (1.0%) 0 3 (17.6%) 6 (2.4%) 0.002
Laboratory values, median
Platelet count, ×103/μl 130.5 108.5 128.0 134.5 128.0 122.0 0.19
ALP, U/l 99.0 94.5 114.0 130.5 124.0 114.0 0.0001
AST, U/l 93.5 85.5 68.0 90.0 104.0 80.0 0.01
Total bilirubin, mg/dl 1.0 1.1 1.2 1.2 3.8 1.2 <0.0001
INR 1.0 1.1 1.1 1.1 1.5 1.1 <0.0001
Albumin, g/dl 3.6 3.4 3.3 3.2 2.3 3.3 <0.0001
Creatinine, mg/dl 0.9 0.9 1.0 1.0 0.9 1.0 0.03
α-Fetoprotein, median, ng/ml 17.7 24.6 34.3 1006.9 19.6 31.2 <0.0001
≤200, n (%) 8 (100%) 67 (88.2%) 76 (72.4%) 19 (39.6%) 13 (76.5%) 183 (72.1%) <0.0001
201–400, n (%) 0 4 (5.3%) 3 (2.9%) 1 (2.1%) 0 8 (3.2%)
>400, n (%) 0 3 (4.0%) 25 (23.8%) 23 (47.9%) 3 (17.7%) 54 (21.3%)
MELD score, mediana 7.5 9.2 9.8 9.9 16.4 9.7 <0.0001
Low, < 15, n (%) 225 (88.6%) 5 (29.4%) 45 (93.8%) 97 (92.4%) 70 (92.1%) 8 (100%) <0.0001
Moderate–high, ≥15, n (%) 29 (11.4%) 12 (70.6%) 3 (6.3%) 8 (7.6%) 6 (7.9%) 0
Child–Pugh class, n (%)b
A 7 (87.5%) 45 (59.2%) 55 (52.4%) 29 (60.4%) 0 136 (53.5%) <0.0001
B 1 (12.5%) 31 (40.8%) 50 (47.6%) 18 (37.5%) 1 (5.9%) 101 (39.8%)
C 0 0 0 0 16 (94.1%) 16 (6.3%)
aMELD scores were used to assess the severity of chronic liver disease.27
bThe Child–Pugh system evaluates the severity of liver disease and prognosticate outcome. Patients are divided into classes A to C, with class C
indicating the worst prognosis.26,28
cP-values were calculated from Fisher's exact test or chi-squared tests for categorical variables and ANOVA for continuous variables. Continuous
variables were rank-transformed as appropriate.
SD, standard deviation; BMI, body mass index; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; AST, aspartate
aminotransferase; ALP, alkaline phosphatase; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease.
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patients remained alive without evidence of recurrent HCC.
Reasons why patients with BCLC stage 0–A disease did not
undergo liver transplantation included advanced age, medical
comorbidity, patient preference and lack of social support. In
addition, some patients remained on waitlists for transplant at the
study end date.
The results of proportional hazards analysis examining the sur-
vival effects of the most curative treatments in non-transplanted
early-stage (BCLC stage 0–A) and intermediate-stage (BCLC stage
B) patients are presented in Table 5. Among patients with BCLC
stage 0–A disease, RFA and resection were associated with signifi-
cantly improved 1-year survival compared with no treatment [for
death: HR = 0.13, 95% confidence interval (CI) 0.02–0.78, and HR
= 0.19, 95% CI 0.04–0.88, respectively]. At 5 years, the hazard for
death was markedly reduced in patients with BCLC stage 0–A
disease in receipt of any form of therapy compared with those
without treatment (LRT: HR = 0.11, 95%CI 0.02–0.58; RFA: HR =
0.08, 95% CI 0.02–0.40; resection: HR = 0.05, 95% CI 0.01–0.26).
Among non-transplanted patients with BCLC stage B disease,
RFA and resection reduced the hazard for death at 1 year in
comparison with no treatment (HR = 0.10, 95% CI 0.02–0.47 and
HR = 0.23, 95% CI 0.06–0.85, respectively) (Table 5). At 5 years,
only resection yielded a significant benefit (HR = 0.27, 95% CI
0.12–0.80), whereas RFA was associated with amarginally reduced
hazard for death (HR = 0.54, 95% CI 0.27–1.10). A comparison of
the effects of resection or RFA with those of LRT in patients with
BCLC stage B disease showed RFA to confer a survival benefit at 1
year (HR = 0.17, 95% CI 0.04–0.74) and resection to be associated
with improved survival at 5 years (HR = 0.31, 95% CI 0.14–0.66).
These results are illustrated in 1- and 5-year Kaplan–Meier sur-
vival curves for patients with BCLC stage B disease stratified by
three treatment modalities (Fig. 1).
Discussion
This study describes treatment and survival experiences in a
mixed-stage cohort of HCC patients at a large tertiary care VA
medical centre. Overall, 75.1% of patients evaluated for treatment
had early- or intermediate-stage disease (33.8% had BCLC stage
0–A disease and 41.3% had BCLC stage B disease). These findings
contrast favourably with recent reports from population-based
Surveillance, Epidemiology and End Results (SEER) and VA
patient registries, which indicated that 45% and 29% of HCC
patients, respectively, had BCLC stage 0–B disease at diagno-
sis.7,12,20 The larger proportion of earlier-stage patients seen at the
study centre reflects the vigilant approach to the surveillance of
at-risk patients at this hospital and its affiliates, but also is a
function of the cohort’s inclusion of only patients referred for
HCC treatment. Liver transplantation, the treatment of choice for
HCC patients, was performed in only a small minority of cases
and had a limited impact on overall survival. Only 11 (4.3%)
patients underwent transplant, 10 of whom had BCLC stage 0–A
disease, comprising 11.9% of those presenting within the Milan
criteria.17 Not surprisingly, these proportions correspond almost
exactly with those reported by Davila et al. in their recent VAHCV
registry-based review, in which they found liver transplant rates of
11.6% in patients with BCLC stage A disease and 3.2% in HCC
patients overall.7 A complex combination of factors, including age,
comorbidities, substance use and organ shortage, contribute to
the low rate of transplantation among VA patients. The present
experience is reflective of those at other interventional centres at
which the underutilization of transplant in HCC patients has been
noted.21 There is a worldwide debate on whether liver transplan-
tation is a practical therapeutic option for HCC, given its increas-
ing incidence and the relative shortage of organs. The low number
of transplants performed in health care settings such as that of the
present study, at which comprehensive care and treatment are
available, reflect these concerns. Persistent obstacles to transplan-
tation have motivated this centre’s active pursuit of alternative
curative treatments for early- and intermediate-stage HCC.
Whereas few patients in the present cohort underwent liver
transplantation, the majority received some form of liver-directed
therapy during follow-up, including 93.4% of patients with BCLC
Table 2 Tumour characteristics in patients with hepatocellular carcinoma by Barcelona Clinic Liver Cancer (BCLC) stage at the index visit
Tumour characteristics BCLC stage Total
(n = 254)
P-valuea
0
(n = 8)
A
(n = 76)
B
(n = 105)
C
(n = 48)
D
(n = 17)
Number of lesions, n (%)
1 8 (100%) 49 (64.5%) 31 (29.5%) 24 (50.0%) 7 (41.2%) 119 (46.9%) <0.0001
2 0 15 (19.7%) 27 (25.7%) 4 (8.3%) 4 (23.5%) 50 (19.7%)
3 0 11 (14.5%) 19 (18.1%) 3 (6.3%) 2 (11.8%) 36 (14.2%)
4 or 5 0 0 11 (10.5%) 3 (6.3%) 0 14 (5.5%)
>5 0 0 17 (16.2%) 14 (29.2%) 4 (23.5%) 35 (13.8%)
Largest tumour size, median, cm 1.5 2.7 5.0 6.9 4.6 4 <0.0001
<3 cm, n (%) 7 (87.5%) 57 (75%) 14 (13.3%) 5 (10.4%) 6 (35.3%) 89 (35.0%) <0.0001
3–5 cm, n (%) 1 (12.5%) 18 (23.7%) 41 (39.1%) 10 (20.8%) 3 (17.7%) 73 (28.7%)
>5 cm, n (%) 0 1 (1.3%) 50 (47.6%) 33 (68.8%) 8 (47.1%) 92 (36.2%)
aP-values were calculated using Fisher's exact test or chi-squared tests for categorical variables; continuous variables were rank-transformed.
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Table 3 Treatment modalities in patients with hepatocellular carcinoma by Barcelona Clinic Liver Cancer (BCLC) stage at the index visit
Characteristics BCLC stage Total
(n = 254)
P-valued
0
(n = 8)
A
(n = 76)
B
(n = 105)
C
(n = 48)
D
(n = 17)
Number of treatment modalities used, median
(range) (n = 192)
2 (1–3) 2 (1–11) 2 (1–9) 1 (1–5) 2 (1–4) 2 (1–11)
All treatment modalities received, n (%)a
Transplant 2 (25%) 8 (10.5%) 1 (1.0%) 0 0 11 (4.3%) 0.0009
Surgical resection 3 (37.5%) 23 (32.9%) 21 (20.0%) 3 (6.3%) 1 (5.9%) 53 (20.9%) 0.001
RFA 4 (50.0%) 30 (39.5%) 23 (21.9%) 2 (4.2%) 1 (5.9%) 60 (23.6%) <0.0001
MWA 0 3 (3.9%) 5 (4.8%) 0 0 8 (3.1%) 0.63
TACE 2 (25%) 13 (17.1%) 23 (21.0%) 8 (16.7%) 1 (5.9%) 47 (18.1%) 0.55
TAE 3 (37.5%) 33 (43.4%) 51 (48.6%) 15 (31.3%) 4 (23.5%) 106 (41.7%) 0.16
PEI 1 (12.5%) 11 (14.5%) 23 (21.9%) 3 (6.3%) 3 (17.6%) 41 (16.1%) 0.15
Chemotherapy 2 (25.5%) 11 (14.4%) 16 (15.3%) 12 (25.0%) 0 41 (16.1%) 0.49
Never treated 0 4 (5.3%) 16 (15.2%) 20 (41.7%) 11 (64.7%) 51 (20.1%) <0.0001
First treatment modality received, n (%)
Transplant 0 0 0 0 0 0 <0.0001
Surgical resection 3 (37.5%) 23 (30.3%) 17 (16.2%) 2 (4.2%) 1 (5.9%) 46 (18.1%)
RFA 4 (50.0%) 25 (32.9%) 13 (12.4%) 1 (2.1%) 0 43 (16.9%)
Locoregional therapyb 1 (12.5%) 23 (30.2%) 58 (55.2%) 19 (39.5%) 5 (29.4%) 106 (41.7%)
Chemotherapy or none 0 5 (6.6%) 17 (16.2%) 26 (54.2%) 11 (64.7%) 59 (23.2%)
Most potentially efficacious treatment received, n (%)
Transplant 2 (25.0%) 8 (10.5%) 1 (1.0%) 0 0 11 (4.3%) <0.0001
Surgical resection 3 (37.5%) 24 (31.6%) 21 (20.0%) 3 (6.3%) 1 (5.9%) 52 (20.5%)
RFA 2 (25.0%) 20 (26.3%) 20 (19.0%) 2 (4.2%) 1 (5.9%) 45 (17.7%)
Locoregional therapyb 1 (12.5%) 19 (25.0%) 46 (43.8%) 17 (35.4%) 4 (23.5%) 87 (34.3%)
Chemotherapy or nonec 0 5 (6.6%) 17 (16.2%) 26 (54.2%) 11 (64.7%) 59 (23.2%)
aThe percentages in this section of the table exceed the number/percentages of patients listed at the head of each column as patients may have
received multiple treatments.
bLocoregional therapy includes: PEI, MWA, TA(C)E.
cEight patients received chemotherapy.
dP-values were calculated from Fisher's exact test or chi-squared tests for categorical variables; continuous variables were rank-transformed.
RFA, radiofrequency ablation; LRT, locoregional therapy; MWA, microwave ablation; TAE, transarterial embolization; TACE, transarterial
chemoembolization; PEI, percutaneous ethanol injection.
Table 4 Median survival time and percentage survival at 1, 2, 3 and 5 years in patients with hepatocellular carcinoma by Barcelona Clinic
Liver Cancer (BCLC) stage at the index visit
Characteristics BCLC stage Total
(n = 254)
P-valuea
0
(n = 8)
A
(n = 76)
B
(n = 105)
C
(n = 48)
D
(n = 17)
Median survival, months 23.5 19.5 18.0 50 3.0 16.0 <0.0001
Overall survival, %
1-year (n = 247)b 100% 83.3% 67.6% 29.2% 29.4% 63.2% <0.0001
2-year (n = 223)b 57.1% 57.6% 40.9% 14.9% 17.6% 38.6% <0.0001
3-year (n = 213)b 57.1% 42.6% 23.3% 8.9% 11.8% 25.4% 0.0004
5-year (n = 199)b 33.3% 25.5% 9.4% 0% 6.3% 11.6% 0.001
aP-values were calculated using Fisher's exact test or chi-squared tests for categorical variables; continuous variables were rank-transformed.
bFor each time period, the number used to calculate percentage survival includes patients who died during follow-up and those remaining alive and
not lost to follow-up at the end of the designated time period.
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stage 0–A disease, 83.8% of those with stage B, and 56.9% of those
with stage C–D disease. This centre’s aggressive use of these inter-
ventions contrasts with reports from SEER, Medicare and VA
studies, in which only 30–34% of HCC patients are reported to
have received any form of liver-directed treatment.7,12 Despite the
present aggressive approach, only 11.6% of the cohort survived ≥5
years, a finding that aligns with the 5-year survival rates of 17.9%
and 8.6% reported in recent studies.30,31 Longterm survival was
essentially confined to patients who underwent liver transplanta-
tion or curative resection.
Resection and RFA are widely appreciated as effective treatment
strategies, either as first-line treatment or as part of a multimodal
approach.32 In the present study, only 15 of the 24 patients with
BCLC stage A disease who underwent resection had been followed
for 5 years by the study end date. Of those, four (26.7%) patients
survived ≥5 years. These disappointing outcomes are attributable
in part to the high proportion of patients with BCLC stage A
disease and Child–Pugh class B status at presentation or with
unfavourable tumour characteristics, resulting in a poor progno-
sis. In several cases, the surgeons at the present centre resected
lesions of >5 cm in size if they were located in favourable loca-
tions. In a retrospective study of patients from six hospitals in
three countries, investigators found a 5-year survival rate of 66%
following resection in Child–Pugh class A patients with a single
nodule measuring up to 5 cm.33 An Italian study of resection of
tumours of <3 cm in size found a 5-year survival rate of 53%.34
The outcomes reported by these studies are comparable with the
benchmark 5-year survival rates of 65–75% achieved after liver
transplantation in patients within the Milan criteria.17,34,35
Radiofrequency ablation alone can also achieve benefits. A recent
review of eight non-randomized studies comparing RFA with
resection for HCC found comparable overall 5-year survival rates
(41–77% for RFA; 54–80% for resection).36 Although no statisti-
cally significant difference in survival was detected, resected
patients had significantly lower rates of recurrence and higher
rates of disease-free survival. The current findings also demon-
strate that RFA diminishes the risk for death in patients with stage
0–A disease, and support previously reported evidence that both
surgical resection and RFA are potentially beneficial in BCLC stage
0–A HCC.
The optimal therapy in BCLC stage B disease has not been
empirically defined. Typically, these patients are not considered
candidates for liver transplantation, surgical resection or RFA
because they are thought to be too medically compromised to
tolerate these procedures.17,20,37 A recent assessment of HCC
patients in theVA system, however, found that 42% of 265 patients
with BCLC stage B disease received some form of therapy, includ-
ing liver transplant (3%), resection (9%), ablation (12%), TACE
(25%) and systemic chemotherapy (6%).7 Among the present
BCLC stage B group, 20.0% underwent surgical resection and
19.0% submitted to RFA as their most potentially efficacious
therapy. One patient with BCLC stage B disease received a liver
Table 5 Proportional hazards analyses at 1 year and 5 years in non-transplanted hepatocellular carcinoma patients with Barcelona Clinic
Liver Cancer (BCLC) stage 0–A and B disease, by most efficacious treatment
HRs comparing most efficacious treatment with no treatment at 1 year and 5 years
Treatment modality 1-year HRc (95% CI) P-valued 5-year HRc (95% CI) P-valued
BCLC stage 0–A (n = 73a)
Chemotherapy or no treatment Reference Reference
Locoregional therapyb 0.24 (0.05–1.23) 0.9 0.11 (0.02–0.56) 0.002
Radiofrequency ablation 0.13 (0.02–0.78) 0.03 0.08 (0.02–0.40) 0.008
Resection 0.19 (0.04–0.88) 0.03 0.05 (0.01–0.26) 0.0003
BCLC stage B (n = 104a)
Chemotherapy or no treatment Reference Reference
Locoregional therapyb 0.57 (0.26–1.27) 0.17 0.82 (0.44–1.51) 0.52
Radiofrequency ablation 0.10 (0.02–0.47) 0.003 0.54 (0.27–1.10) 0.09
Resection 0.23 (0.06–0.85) 0.03 0.27 (0.12–0.60) 0.002
HRs at 1 year and 5 years comparing most efficacious treatment with LRT in non-transplanted patients with BCLC stage B diseasea
Treatment modality 1-year HRc (95% CI) P-valued 5-year HRc (95% CI) P-valued
Locoregional therapyb Reference Reference
Radiofrequency ablation 0.17 (0.04–0.74) 0.02 0.63 (0.34–1.11) 0.13
Resection 0.38 (0.11–1.33) 0.13 0.31 (0.14–0.66) 0.002
aTransplant patients (10 BCLC stage 0–A and one BCLC stage B) were excluded from these analyses.
bLRTs include microwave ablation, transarterial embolization, transarterial chemoembolization and percutaneous ethanol injection.
cAge-adjusted HRs were calculated using Cox proportional hazards modelling in SAS Version 9.2.
dP-values were calculated using Fisher's exact test or chi-squared tests for categorical variables; continuous variables were rank-transformed.
HR, hazards ratio; 95% CI, 95% confidence interval; LRT, locoregional therapy.
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Figure 1 Probability of remaining alive at (a) 1 year and (b) 5 years by most efficacious treatment modality received in hepatocellular
carcinoma patients with Barcelona Clinic Liver Cancer (BCLC) stage B disease. (a) Kaplan–Meier curves indicate that the use of aggressive
therapy confers a statistically significant survival benefit compared with the use of locoregional therapies (LRTs) at 1 year among patients
with BCLC stage B disease. (b) Patients who underwent hepatic resection achieved a statistically significant increase in the probability of
remaining alive at 5 years compared with those undergoing LRTs
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transplant. Compared with LRT, RFA afforded a survival benefit at
1 year and surgical resection improved 5-year survival among
those with BCLC stage B disease. These results support recent
findings of favourable outcomes in BCLC stage B disease of
aggressive therapy with either resection or liver transplanta-
tion.21,33 Thus, the present authors conclude that potentially cura-
tive procedures can be safely administered to selected patients
with BCLC stage B disease. The current findings are in accordance
with the proposed sub-classification of BCLC stage B, made by
participants in a recent consensus conference, to facilitate curative
treatment when feasible.38
In summary, the present study is one of the first to describe in
detail the treatment experiences of an entire clinical cohort under-
going serial curative and palliative treatments for HCC over time.
The total, first and most curative treatments received are pre-
sented in order to provide a dynamic view of the study centre’s
multimodal approach. The most potentially curative treatment
was not always the first treatment used, even among non-
transplanted patients. Moreover, the present study suggests an
evolving treatment paradigm for patients with intermediate-stage
(BCLC stage B) HCC, who may benefit from the selective appli-
cation of potentially curative therapies that are not typically rec-
ommended by current societal guidelines.
Acknowledgements
The authors would like to acknowledge Amit Arunkumar, BS, for assistance
with data collection, and Francis Yao, MD, Norah Terrault, MD, Marion Peters,
MD, Bilal Hameed, MD, Jennifer Lai, MD, Mandana Khalili, MD, and James
Ostroff, MD, for their expert guidance, and Kenneth R. McQuaid, MD, for his
support and encouragement. The authors would also like to express their
gratitude to the patients in this study, who gave them the opportunity to study
hepatocellular carcinoma through their experiences and to contribute to the
advancement of medical care.
Conflicts of interest
None declared.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. (2011) Global
cancer statistics. CA Cancer J Clin 61:69–90.
2. Centers for Disease Control and Prevention. (2010) Hepatocellular carci-
noma – United States, 2001–2006. MMWR Morb Mortal Wkly Rep
59:517–520.
3. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. (2010) Hepatocellular
carcinoma confirmation, treatment, and survival in surveillance, epidemi-
ology, and end results registries, 1992–2008. Hepatology 55:476–482.
4. Altekruse SF, McGlynn KA, Reichman ME. (2009) Hepatocellular carci-
noma incidence, mortality, and survival trends in the United States from
1975 to 2005. J Clin Oncol 27:1485–1491.
5. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. (2004) Hepa-
titis C infection and the increasing incidence of hepatocellular carcinoma:
a population-based study. Gastroenterology 127:1372–1380.
6. Center for Quality Management in Public Health. (2010) The State of Care
for Veterans with Chronic Hepatitis C. Palo Alto, CA: Public Health Stra-
tegic Health Care Group, US Department of Veterans Affairs, Health
CfQMiP.
7. Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH et al.
(2013) Referral and receipt of treatment for hepatocellular carcinoma in
United States veterans: effect of patient and non-patient factors.
Hepatology 57:1858–1868.
8. Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder
JL et al. (2005) Elevated prevalence of hepatitis C infection in users of
United States veterans medical centres. Hepatology 41:88–96.
9. Lurje G, Lesurtel M, Clavien PA. (2013) Multimodal treatment strategies
in patients undergoing surgery for hepatocellular carcinoma. Dig Dis
31:112–117.
10. Belghiti J. (2009) Resection and liver transplantation for HCC. J
Gastroenterol 44 (Suppl. 19):132–135.
11. Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z
et al. (2011) Utilization of surveillance for hepatocellular carcinoma
among hepatitis C virus-infected veterans in the United States. Ann
Intern Med 154:85–93.
12. Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. (2011)
Underutilization of therapy for hepatocellular carcinoma in the Medicare
population. Cancer 117:1019–1026.
13. Llovet JM. (2002) Evidence-based medicine in the treatment of hepato-
cellular carcinoma. J Gastroenterol Hepatol 17 (Suppl. 3):428–433.
14. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al. (2002)
Randomized controlled trial of transarterial lipiodol chemoembolization
for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171.
15. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. (2002) Longterm survival and
pattern of recurrence after resection of small hepatocellular carcinoma in
patients with preserved liver function: implications for a strategy of
salvage transplantation. Ann Surg 235:373–382.
16. Yopp AC, Subramanian M, Jain MK, Mansour JC, Schwarz RE, Balch GC
et al. (2012) Presentation, treatment, and clinical outcomes of patients
with hepatocellular carcinoma, with and without human immunodefi-
ciency virus infection. Clin Gastroenterol Hepatol 10:1284–1290.
17. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al.
(1996) Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. N Engl J Med 334:693–700.
18. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al.
(2001) Liver transplantation for hepatocellular carcinoma: expansion of
the tumour size limits does not adversely impact survival. Hepatology
33:1394–1403.
19. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF,
Clary BM et al. (2009) NCCN clinical practice guidelines in oncology:
hepatobiliary cancers. J Natl Compr Canc Netw 7:350–391.
20. Bruix J, Sherman M. (2011) Management of hepatocellular carcinoma: an
update. Hepatology 53:1020–1022.
21. D’Avola D, Inarrairaegui M, Pardo F, Rotellar F, Marti P, Bilbao JI et al.
(2011) Prognosis of hepatocellular carcinoma in relation to treatment
across BCLC stages. Ann Surg Oncol 18:1964–1971.
22. Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB et al. (2011)
Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial
chemoembolization plus radiofrequency ablation versus radiofrequency
ablation alone. Ann Surg Oncol 18:1624–1629.
23. Piscaglia F, Bolondi L. (2010) The intermediate hepatocellular carcinoma
stage: should treatment be expanded? Dig Liver Dis 42 (Suppl. 3):258–
263.
24. Bruce-Chwatt LJ. (1965) Declaration of Helsinki. Recommendations
Guiding Doctors in Clinical Research. WHO Chron 19:31–32.
25. Schuckit MA. (2009) Alcohol-use disorders. Lancet 373:492–501.
766 HPB
HPB 2014, 16, 758–767 © 2014 International Hepato-Pancreato-Biliary Association
26. Child CGI, ed. (1964) The Liver and Portal Hypertension. Vol. 1 of Major
Problems in Clinical Surgery. Philadelphia, PA: W B Saunders.
27. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC.
(2000) A model to predict poor survival in patients undergoing
transjugular intrahepatic portosystemic shunts. Hepatology 31:864–
871.
28. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. (1973)
Transection of the oesophagus for bleeding oesophageal varices. Br J
Surg 60:646–649.
29. Chang TT, Sawhney R, Monto A, Davoren JB, Kirkland JG, Stewart L
et al. (2008) Implementation of a multidisciplinary treatment team for
hepatocellular cancer at a Veterans Affairs Medical Center improves
survival. HPB 10:405–411.
30. Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday
CJ. (2010) Racial/ethnic disparities in access to care and survival for
patients with early-stage hepatocellular carcinoma. Arch Surg 145:1158–
1163.
31. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh
JW et al. (2007) Survival for eight major cancers and all cancers com-
bined for European adults diagnosed in 1995–99: results of the
EUROCARE-4 study. Lancet Oncol 8:773–783.
32. Colombo M, Raoul JL, Lencioni R, Galle PR, Zucman-Rossi J, Banares R
et al. (2013) Multidisciplinary strategies to improve treatment outcomes in
hepatocellular carcinoma: a European perspective. Eur J Gastroenterol
Hepatol 25:639–651.
33. Silva MF, Sapisochin G, Strasser SI, Hewa-Geeganage S, Chen J, Wigg
AJ et al. (2013) Liver resection and transplantation offer similar 5-year
survival for Child–Pugh–Turcotte A HCC patients with a single nodule up
to 5 cm: a multicentre, exploratory analysis. Eur J Surg Oncol 39:386–
395.
34. Giuliante F, Ardito F, Pinna AD, Sarno G, Giulini SM, Ercolani G et al.
(2012) Liver resection for hepatocellular carcinoma ≤3 cm: results of an
Italian multicentre study on 588 patients. J Am Coll Surg 215:244–254.
35. Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A et al.
(2011) Which matters most: number of tumours, size of the largest
tumour, or total tumour volume? Liver Transpl 17 (Suppl. 2):58–66.
36. Tiong L, Maddern GJ. (2011) Systematic review and meta-analysis of
survival and disease recurrence after radiofrequency ablation for hepa-
tocellular carcinoma. Br J Surg 98:1210–1224.
37. Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP et al.
(2011) Multidisciplinary Canadian consensus recommendations for the
management and treatment of hepatocellular carcinoma. Curr Oncol
18:228–240.
38. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F
et al. (2012) Heterogeneity of patients with intermediate (BCLC B) hepa-
tocellular carcinoma: proposal for a subclassification to facilitate treat-
ment decisions. Semin Liver Dis 32:348–359.
Supporting information
Additional supporting information may be found in the online version of this
article at the publisher's website:
Figure S1. Probability in hepatocellular carcinoma patients of remaining alive
at (a) 1 year (n = 247 patients) and (b) 5 years (n = 199 patients) by Barcelona
Clinic Liver Cancer (BCLC) stage at the index visit. Kaplan–Meier curves reveal
that both patients with early-stage disease (BCLC stage 0–A) and patients
with intermediate-stage disease (BCLC stage B) achieved a statistically sig-
nificant improvement in survival at both 1 year and 5 years compared with
patients with advanced-stage disease (BCLC stage C–D) (P < 0.0001 for each
paired comparison, respectively).
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